Generic Name: vismodegib

Trade Name: Erivedge™

How is this drug used? Erivedge is approved for the treatment of adults with basal cell carcinoma of the skin that has spread to other parts of the body or that has come back after surgery or cannot be treated with surgery or radiation. It is important for patients to remember that physicians have the ability to prescribe medication for conditions other than those for which the drug has been approved by the FDA. Patients who have received a prescription of this drug for a condition other than for which it is approved may wish to discuss this issue with their physician.

What is the mechanism of action? Erivedge targets a specific biological pathway (the Hedgehog pathway) that is thought to play a role in more than 90% of cases of basal cell carcinoma. Erivedge inhibits the abnormal signaling in this pathway that contributes to cancer growth.

How is Erivedge given (administered)? Erivedge is taken orally (by mouth).

How are patients monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Erivedge.  Typically, blood will be drawn to check levels of blood cells and to monitor functions of some organ systems. Patients may undergo physical examinations and other tests to assess side effects and response to therapy.

What are the most common side effects of treatment with Erivedge?

• Muscle spasms
• Hair loss
• Taste changes or loss of taste
• Weight loss
• Fatigue
• Nausea
• Diarrhea
• Decreased appetite
• Constipation
• Joint pain
• Vomiting

This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.
What can patients do to help alleviate or prevent discomfort and side effects?

• Pay careful attention to the physician’s instructions, and discuss side effects with your physician.

Are there any special precautions patients should be aware of before starting treatment?

• Patients should inform their physician if they are pregnant, breastfeeding or planning a family in the near future. Erivedge can cause severe birth defects and fetal death. Women should have a pregnancy test prior to starting Erivedge and should talk with their doctor about choice and duration of birth control.
• Men treated with Erivedge should use a condom and spermicide during sex (even if they’ve had a vasectomy) to avoid exposing their partner to Erivedge through semen.
• During treatment and for several months afterwards, patients should not donate blood or blood products.
• Patients should inform their physician about all other medical conditions.
• Patients should inform their physician of any other medication or supplement they are taking (whether prescription or over-the-counter).

When should patients notify their physician?

Tell your doctor if you experience any side effects that bother you or don’t go away.

What is a package insert?
A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers.  A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.

Copyright © 2012 CancerConnect Last updated 01/12.

Important Limitations of Use

The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor.  We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.

As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information.  Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment in selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.

DISCLAIMER OF WARRANTIES

CANCERCONSULTANTS.COM SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN.  CANCERCONSULTANTS.COM DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.

Generic Name: axitinib

Trade Name: Inlyta®

How is this drug used? Inlyta is FDA approved for the treatment of advanced renal cell carcinoma (kidney cancer) after one prior drug treatment has not worked. It is important for patients to remember that physicians have the ability to prescribe medication for conditions other than those for which the drug has been approved by the FDA. Patients who have received a prescription of this drug for a condition other than for which it is approved may wish to discuss this issue with their physician.

What is the mechanism of action?  Inlyta is a type of drug known as a kinase inhibitor. It works by blocking certain proteins that play a role in cancer growth

How is Inlyta typically given (administered)? Inlyta is taken orally (by mouth), typically twice per day.

How are patients typically monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Inlyta. Typically, blood will be drawn to check levels of blood cells and to monitor functions of some organ systems. Physical examinations, scans or other measures may also be utilized to assess side effects and response to therapy.

What are the most common side effects of treatment with Inlyta?

• Diarrhea
• High blood pressure
• Fatigue
• Decreased appetite
• Nausea
• Hoarseness
• Hand-foot syndrome
• Weight loss
• Vomiting
• Weakness
• Constipation

What are some of the less common side effects to be aware of?

• Blood clots
• Bleeding problems
• A tear (perforation) in the stomach or intestine
• Thyroid problems
• Reversible posterior leukoencephalopathy syndrome (a condition that involves swelling in the brain).
• Increased protein in the urine
• Changes in liver function

This is not a complete list of side effects. Some patients may experience other side effects that are not listed above. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.

What can patients do to help alleviate or prevent discomfort and side effects?

• Pay careful attention to the physician’s instructions and inform the physician of any side effects.
• Do not eat grapefruit or drink grapefruit juice. Grapefruit may increase the amount of Inlyta in the blood.
• Maintain adequate rest and nutrition.
• Eat small meals frequently to help alleviate nausea.
• Drink plenty of fluids (patients should ask their physician about the amount of liquid to consume during a day).

Are there any special precautions patients should be aware of before starting treatment?

• Patients should inform their physician if they are pregnant, breastfeeding, or planning a family in the near future. This drug may cause birth defects. It is important to use a form of birth control while undergoing treatment.
• It is important that patients inform their physician of any pre-existing conditions, including high blood pressure, thyroid problems, liver problems, history of blood clots or bleeding problems, history of heart attack or stroke, or an unhealed wound.
• Patients should inform their physician about any planned surgery.
• Patients should inform their physician of any other medication they are taking (whether prescription or over-the-counter, including vitamins, herbs, etc.) as they may interfere with treatment.
• Patients should check with their physician before starting any new drug or nutritional supplement.
• Patients should inform their physician of any known drug or food allergies or any reactions to medications they have experienced in the past.

When should patients notify their physician?

Tell your doctor if you experience any side effects that bother you or don’t go away. Also call if you notice signs of thyroid problems (e.g. persistent tiredness, feeling hot or cold, weight gain or loss, voice deepening, hair loss, or muscle cramps), signs of a blood clot (e.g. chest pain or pressure; pain in arms, back, neck, or jaw; shortness of breath; numbness or weakness on one side of the body; trouble talking; headache; vision problems), signs of unusual bleeding  (e.g. bleeding that is heavy or persistent, pink or brown urine, red or black stools, unusual bruising, coughing up or vomiting blood, unexpected pain or swelling; headache or dizziness), signs of a gastrointestinal tear (e.g. severe stomach pain, bloody vomit, red or black stools), or signs of brain problems (e.g headache, seizure, weakness, confusion, high blood pressure, blindness or change in vision, problems thinking).

What is a package insert?

A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug by healthcare providers and consumers. A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics, and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.

Copyright © 2012 CancerConnect Last updated 01/12.

Important Limitations of Use

The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor. We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.

As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information. Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment in selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.

DISCLAIMER OF WARRANTIES

CANCERCONSULTANTS.COM SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN. CANCERCONSULTANTS.COM DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.

Generic Name: vemurafenib

Trade Name: Zelboraf™

How is this drug used? Zelboraf is used for the treatment of melanoma that has metastasized or cannot surgically removed and that tests positive for a specific mutation (V600E) in the BRAF gene.

What is the mechanism of action? Approximately half of all late-stage melanomas have a mutation known as V600E in the BRAF gene. Zelboraf inhibits the protein produced by this mutated gene and helps to control cell growth.

How is Zelboraf given (administered)? Zelboraf is taken orally (by mouth).

How are patients monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Zelboraf. Typically, blood will be drawn to check levels of blood cells and to monitor functions of some organ systems. Patients will undergo skin examinations in addition to other tests to assess side effects and response to therapy.

What are the most common side effects of treatment with Zelboraf?

• Joint pain
• Rash
• Hair loss
• Fatigue
• Sunburn or sun sensitivity
• Nausea
• Itching
• Warts

What are some of the less common but potentially serious side effects of Zelboraf?

Zelboraf may cause a type of skin cancer known as cutaneous squamous cell carcinoma. This type of skin cancer does not usually spread to other parts of the body, but patients should notify their physician if they notice a new wart, a skin sore or reddish bump that bleeds or does not heal, or a change in the size or appearance of a mole.

Other potentially serious side effects include the following:

• Allergic reaction
• Severe skin reaction
• A change in the electrical activity of the heart called QT prolongation
• Abnormal liver function tests
• Eye problems
• New melanomas

This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.
What can patients do to help alleviate or prevent discomfort and side effects?

• Pay careful attention to the physician’s instructions, and discuss side effects with your physician.
• Avoid sunlight during treatment with Zelboraf. When you go outside, wear sun-protective clothing and use broad-spectrum, high-SPF sunscreen and lip balm.

Are there any special precautions patients should be aware of before starting treatment?

• Patients should inform their physician about all medical conditions, including problems with the heart, kidneys, or liver; low blood levels of potassium, calcium, or magnesium; and planned surgical, dental, or other medical procedures.
• Patients should inform their physician of any other medication or supplement they are taking (whether prescription or over-the-counter), including blood thinners, anti-fungal medicines, antibiotics, HIV medicines, seizure medicines, antidepressants, and medicines to treat irregular heart beat.
• Patients should inform their physician if they are pregnant, breastfeeding or planning a family in the near future. Zelboraf may harm an unborn baby.

When should patients notify their physician?

Tell your doctor if you experience any side effects that bother you or don’t go away. Watch for signs of serious side effects and report these to your doctor immediately: possible signs of a new skin cancer include a new wart, a skin sore or reddish bump that bleeds or does not heal, and a change in the size or color of a mole; symptoms of an allergic reaction include rash or redness all over the body, feeling faint, trouble breathing or swallowing, throat tightness or hoarseness, fast heartbeat, and swelling of the face, lips, or tongue; symptoms of a severe skin reaction include blisters on the skin or in the mouth, peeling of the skin, fever, and redness or swelling of the face, hands, or soles of the feet; symptoms of QT prolongation (a heart problem) include feeling faint or lightheaded, dizziness, and a heartbeat that is irregular or fast; symptoms of liver problems include yellowing of the skin or the whites of the eyes, fatigue, dark urine, nausea or vomiting, lack of appetite, and pain on the right side of the stomach; symptoms of eye problems include blurred vision, other vision changes, and eye pain, swelling, or redness.

What is a package insert?
A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers. A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.

Copyright © 2011 CancerConnect Last updated 08/11.

Important Limitations of Use

The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor. We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.

As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information. Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment in selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.

DISCLAIMER OF WARRANTIES

CANCERCONSULTANTS.COM SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN. CANCERCONSULTANTS.COM DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.

Generic Name: crizotinib

Trade Name: Xalkori™

How is this drug used? Xalkori is used for the treatment of locally advanced or metastatic non-small cell lung cancer that tests positive for an abnormality in the anaplastic lymphoma kinase (ALK) gene.

What is the mechanism of action? Between one percent and seven percent of non-small cell lung cancers have an abnormal version of the ALK gene that contributes to the growth and development of cancer cells. Xalkori blocks certain proteins, including the protein produced by the abnormal ALK gene.

How is Xalkori given (administered)? Xalkori is taken orally (by mouth).

How are patients monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Xalkori.  Typically, blood will be drawn to check levels of blood cells and to monitor functions of some organ systems. Patients may undergo physical examinations and other tests to assess side effects and response to therapy.

What are the most common side effects of treatment with Xalkori?

• Vision problems
• Nausea
• Diarrhea
• Vomiting
• Swelling of the hands or feet
• Constipation

What are some of the less common but potentially serious side effects of Xalkori?

• Swelling of the lungs (pneumonitis)
• Liver problems
• Heart problems (QT interval prolongation)

This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.
What can patients do to help alleviate or prevent discomfort and side effects?

• Pay careful attention to the physician’s instructions, and discuss side effects with your physician.
• Do not drink grapefruit juice or eat grapefruit during treatment with Xalkori (it can increase the amount of Xalkori in your body to a harmful level).

Are there any special precautions patients should be aware of before starting treatment?

• Patients should inform their physician about all medical conditions, including problems with the heart, liver, or kidneys.
• Patients should inform their physician of any other medication or supplement they are taking (whether prescription or over-the-counter), including St. John’s Wort, antidepressants, anti-fungal medications, antibiotics, and medicines for tuberculosis, HIV-AIDS, heart conditions, and seizures.
• Patients should inform their physician if they are pregnant, breastfeeding or planning a family in the near future. Xalkori may harm an unborn baby.
• If patients experience vision changes, dizziness, or fatigue while taking Xalkori, they should use caution when driving a car or using machinery.

When should patients notify their physician?

Tell your doctor if you experience any side effects that bother you or don’t go away. Tell your doctor right away if you have any changes to your vision, such as flashes of light, blurred vision, sensitivity to light, or new or increased floaters. Also watch for signs of serious side effects and report these to your doctor immediately: symptoms of lung swelling include new or worsening problems with breathing or shortness of breath, cough, or fever; symptoms of liver problems include a yellowing of the skin or the whites of the eyes, feeling tired, dark or brown urine, nausea or vomiting, decreased appetite, pain on the right side of the stomach, and easy bruising or bleeding; and symptoms of QT interval prolongation (a heart problem) include abnormal heartbeats and feeling dizzy or faint.

What is a package insert?
A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers.  A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.

Copyright © 2011 CancerConnect Last updated 08/11.

Important Limitations of Use

The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor.  We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.

As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information.  Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment in selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.

DISCLAIMER OF WARRANTIES

CANCERCONSULTANTS.COM SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN.  CANCERCONSULTANTS.COM DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.

Generic Name: brentuximab vedotin

Trade Name: Adcetris™

How is this drug used? Adcetris is used for the treatment of Hodgkin lymphoma that has progressed (worsened) after autologous stem cell transplant or has progressed after at least two prior multi-agent chemotherapy regimens in patients who are not candidates for a stem cell transplant. Adcetris is also used for the treatment of systemic anaplastic large cell lymphoma (a type of non-Hodgkin lymphoma) that has progressed after at least one prior multi-agent chemotherapy regimen.

What is the mechanism of action? Adcetris targets a protein known as CD30, which is present on Hodgkin lymphoma cells as well as cells from other cancers, including anaplastic large cell lymphoma. Once Adcetris enters CD30-positive cells, it releases the chemotherapy drug monomethyl auristatin E.

How is Adcetris given (administered)? Adcetris is given as an intravenous (IV) infusion.

How are patients monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Adcetris.  Typically, blood will be drawn to check levels of blood cells and to monitor functions of some organ systems. Patients may undergo physical examinations and other tests to assess side effects and response to therapy.

What are the most common side effects (≥20%) of treatment with Adcetris?

• Low blood cell counts (low levels of white blood cells, red blood cells, and platelets)
• Peripheral sensory neuropathy (a nerve problem that causes pain, numbness, tingling, or swelling of the hands or feet)
• Fatigue
• Nausea
• Upper respiratory tract infection
• Diarrhea
• Fever
• Rash
• Cough
• Vomiting

This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.
What can patients do to help alleviate or prevent discomfort and side effects?

• Pay careful attention to the physician’s instructions and inform the physician of any side effects.
• Maintain adequate rest and nutrition.
• If possible, avoid large crowds or people who are sick or not feeling well, as this drug may leave some patients susceptible to infection.
• Wash hands often to reduce the risk of infection.
• Eat small meals frequently to help alleviate nausea.

Are there any special precautions patients should be aware of before starting treatment?

• Patients should inform their physician about all medical conditions.
• Patients should inform their physician of any other medication or supplement they are taking (whether prescription or over-the-counter).
• Patients should inform their physician if they are pregnant, breastfeeding or planning a family in the near future. Adcetris may harm an unborn baby.

When should patients notify their physician?

Tell your doctor if you experience any side effects that bother you or don’t go away. Also watch for and report symptoms of neuropathy (numbness or tingling in the hands or feet or muscle weakness), infection (fever, chills, cough, or pain on urination), and infusion reaction (fever, chills, rash or breathing problems within 24 hours of infusion).

What is a package insert?
A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers.  A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.

Copyright © 2011 CancerConnect Last updated 08/11.

Important Limitations of Use

The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor.  We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.

As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information.  Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment in selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.

DISCLAIMER OF WARRANTIES

CANCERCONSULTANTS.COM SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN.  CANCERCONSULTANTS.COM DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.

Generic Name: vemurafenib

Trade Name: Zelboraf™

How is this drug used? Zelboraf is used for the treatment of melanoma that has metastasized or cannot surgically removed and that tests positive for a specific mutation (V600E) in the BRAF gene.

What is the mechanism of action? Approximately half of all late-stage melanomas have a mutation known as V600E in the BRAF gene. Zelboraf inhibits the protein produced by this mutated gene and helps to control cell growth.

How is Zelboraf given (administered)? Zelboraf is taken orally (by mouth).

How are patients monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Zelboraf.  Typically, blood will be drawn to check levels of blood cells and to monitor functions of some organ systems. Patients will undergo skin examinations in addition to other tests to assess side effects and response to therapy.

What are the most common side effects of treatment with Zelboraf?

• Joint pain
• Rash
• Hair loss
• Fatigue
• Sunburn or sun sensitivity
• Nausea
• Itching
• Warts

What are some of the less common but potentially serious side effects of Zelboraf?

Zelboraf may cause a type of skin cancer known as cutaneous squamous cell carcinoma. This type of skin cancer does not usually spread to other parts of the body, but patients should notify their physician if they notice a new wart, a skin sore or reddish bump that bleeds or does not heal, or a change in the size or appearance of a mole.

Other potentially serious side effects include the following:

• Allergic reaction
• Severe skin reaction
• A change in the electrical activity of the heart called QT prolongation
• Abnormal liver function tests
• Eye problems
• New melanomas

This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.
What can patients do to help alleviate or prevent discomfort and side effects?

• Pay careful attention to the physician’s instructions, and discuss side effects with your physician.
• Avoid sunlight during treatment with Zelboraf. When you go outside, wear sun-protective clothing and use broad-spectrum, high-SPF sunscreen and lip balm.

Are there any special precautions patients should be aware of before starting treatment?

• Patients should inform their physician about all medical conditions, including problems with the heart, kidneys, or liver; low blood levels of potassium, calcium, or magnesium; and planned surgical, dental, or other medical procedures.
• Patients should inform their physician of any other medication or supplement they are taking (whether prescription or over-the-counter), including blood thinners, anti-fungal medicines, antibiotics, HIV medicines, seizure medicines, antidepressants, and medicines to treat irregular heart beat.
• Patients should inform their physician if they are pregnant, breastfeeding or planning a family in the near future. Zelboraf may harm an unborn baby.

When should patients notify their physician?

Tell your doctor if you experience any side effects that bother you or don’t go away. Watch for signs of serious side effects and report these to your doctor immediately: possible signs of a new skin cancer include a new wart, a skin sore or reddish bump that bleeds or does not heal, and a change in the size or color of a mole; symptoms of an allergic reaction include rash or redness all over the body, feeling faint, trouble breathing or swallowing, throat tightness or hoarseness, fast heartbeat, and swelling of the face, lips, or tongue; symptoms of a severe skin reaction include blisters on the skin or in the mouth, peeling of the skin, fever, and redness or swelling of the face, hands, or soles of the feet; symptoms of QT prolongation (a heart problem) include feeling faint or lightheaded, dizziness, and a heartbeat that is irregular or fast; symptoms of liver problems include yellowing of the skin or the whites of the eyes, fatigue, dark urine, nausea or vomiting, lack of appetite, and pain on the right side of the stomach; symptoms of eye problems include blurred vision, other vision changes, and eye pain, swelling, or redness.

What is a package insert?
A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers.  A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.

Copyright © 2011 CancerConnect Last updated 08/11.

Important Limitations of Use

The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor.  We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.

As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information.  Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment in selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.

DISCLAIMER OF WARRANTIES

CANCERCONSULTANTS.COM SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN.  CANCERCONSULTANTS.COM DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.

Generic Name: Abiraterone

Trade Name: Zytiga™

How is this drug used? Zytiga is used in combination with prednisone for metastatic, castration-resistant prostate cancer that has previously been treated with the chemotherapy drug Taxotere® (docetaxel).

What is the mechanism of action? Zytiga blocks the production of androgens (male hormones such as testosterone) not only by the testes but also by the adrenal glands and the tumor itself.

How is Zytiga given (administered)? Zytiga is a tablet that is taken orally (by mouth). Zytiga is taken on an empty stomach.

How are patients monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Zytiga. Typically, blood will be drawn to check for side effects and to monitor functions of some organ systems. Patients may also undergo physical examinations or other measures to assess side effects and response to therapy.

What are the most common side effects of treatment with Zytiga?

• Joint swelling or discomfort
• Muscle aches
• Hot flushes
• Diarrhea
• Urinary tract infection
• Cough
• Irregular heartbeats
• Frequent urination or need to get up at night to urinate
• Heartburn
• Cold-like symptoms

What are some of the potentially serious side effects of Zytiga?

• High blood pressure
• Low blood potassium levels
• Fluid retention
• Adrenal problems
• Liver problems

This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.

What can patients do to help alleviate or prevent discomfort and side effects?

• Pay careful attention to the physician’s instructions, and discuss side effects with your physician.
• Do not take Zytiga with food.

Are there any special precautions patients should be aware of before starting treatment?

• Patients should inform their physician about all medical conditions, including heart problems, liver problems, and a history of adrenal or pituitary problems.
• Patients should inform their physician of any other medication or supplement they are taking (whether prescription or over-the-counter).
• During treatment with Zytiga and for a week after Zytiga treatment ends, men who are sexually active with a pregnant woman must use a condom. If a man’s sexual partner is not pregnant but could become pregnant, a condom and another effective form of birth control should be used.
• Although Zytiga is not for use in women, a woman who takes Zytiga should tell her doctor if she is pregnant, planning to become pregnant, or breastfeeding. Zytiga may harm an unborn baby. Women who are pregnant or could become pregnant should not touch Zytiga without protection such as gloves.

When should patients notify their physician?

Tell your doctor if you experience any side effects that bother you or don’t go away. Some symptoms of potentially serious side effects include dizziness, fast heartbeats, feeling faint or lightheaded, headache, confusion, muscle weakness, pain in your legs, and swelling in your legs or feet.

What is a package insert?
A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers. A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.

Copyright © 2011 CancerConnect Last updated 05/11.

Important Limitations of Use

The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor. We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.

As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information. Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment in selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.

DISCLAIMER OF WARRANTIES

CANCERCONSULTANTS.COM SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN. CANCERCONSULTANTS.COM DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.

Generic Name: Infliximab

Trade Name: Remicade®

How is this drug used? Remicade is used for selected patients with Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or plaque psoriasis. Remicade does not cure these conditions, but it can reduce symptoms.

What is the mechanism of action? Remicade helps to control the development of inflammation by blocking a protein (tumor necrosis factor-alpha) made by the immune system.

How is Remicade given (administered)? Remicade is given by intravenous (IV) infusion.

How are patients monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Remicade.  Typically, blood will be drawn to check levels of blood cells and to monitor functions of some organ systems. Patients will be monitored for signs and symptoms of tuberculosis (TB), and may also undergo physical examinations or other measures to assess side effects and response to therapy.

What are the most common (occur in more than 10% of patients) side effects of treatment with Remicade?

• Infections
• Infusion-related reactions
• Headache
• Abdominal pain

What are some of the less common but potentially serious side effects of Remicade?

• Serious infection
• Cancer
• Hepatitis B virus reactivation
• Liver problems
• Heart failure
• Low blood cell counts
• Severe allergic reaction
• Worsening or new demyelinating disease
• Lupus-like syndrome

This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.

What can patients do to help alleviate or prevent discomfort and side effects?

• Pay careful attention to the physician’s instructions, and discuss side effects with your physician.

Are there any special precautions patients should be aware of before starting treatment?

• Patients should be tested for tuberculosis (TB) before starting Remicade
• Patients should inform their physician about all medical conditions, including current infections, history of frequent infections, open cuts or sores, diabetes, immune system problems, TB or contact with someone who has TB, hepatitis B, potential exposure to certain fungal infections (the likelihood of exposure varies by region), heart problems, cancer, liver problems, COPD (chronic obstructive pulmonary disease), and nervous system conditions.
• Patients should inform their physician of any other medication or supplement they are taking (whether prescription or over-the-counter), including Kineret® (anakinra), Orencia® (abatacept), and Actemra® (tocilizumab).
• Patients should inform their physician if they have had phototherapy for psoriasis.
• Patients should inform their physician if they have recently received or are scheduled to receive a vaccine.
• Patients should inform their physician if they are pregnant, breastfeeding or planning a family in the near future.

When should patients notify their physician?

Tell your doctor if you experience any side effects that bother you or don’t go away. Call your doctor immediately if you develop an infection or notice signs of an infection such as fever; cough; flu-like symptoms; fatigue; or warm, red, or painful skin. Also call your doctor if you have open cuts or sores, symptoms of heart failure (shortness of breath, swelling of ankles or feet, sudden weight gain), symptoms of liver problems (jaundice, dark brown urine, pain on right side of stomach area, fever, or extreme tiredness), symptoms of low blood cell counts (fever, easy bruising or bleeding, pallor), nervous system problems (changes in vision, weakness in arms or legs, numbness or tingling, seizures), signs of an allergic reaction (hives, difficulty breathing or swallowing, chest pain, high or low blood pressure, fever, chills, rash, headache, sore throat, muscle or joint pain, or swelling of the face and hands), symptoms of a lupus-like syndrome (chest discomfort, shortness of breath, joint pain, rash on cheeks or arms that gets worse in the sun), or new or worsening psoriasis.

What is a package insert?

A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers.  A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.

Copyright © 2011 CancerConnect Last updated 04/11.

Important Limitations of Use

The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor.  We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.

As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information.  Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment in selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.

DISCLAIMER OF WARRANTIES

CANCERCONSULTANTS.COM SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN.  CANCERCONSULTANTS.COM DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.

Generic Name: Ipilimumab

Trade Name: Yervoy™

How is this drug used? Yervoy is used for the treatment of metastatic melanoma or melanoma that cannot be surgically removed.

What is the mechanism of action? Yervoy targets a molecule known as CTLA4. CTLA4 is found on the surface of T cells and is thought to inhibit immune responses. By targeting this molecule, Yervoy may enhance the immune system’s response against tumor cells.

How is Yervoy given (administered)? Yervoy is given as an intravenous (IV) infusion.

How are patients monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Yervoy.  Typically, blood will be drawn to check levels of blood cells and to monitor functions of some organ systems. Patients may also undergo physical examinations or other measures to assess side effects and response to therapy.

What are the most common side effects of treatment with Yervoy?

• Fatigue
• Diarrhea
• Itching
• Rash

What are some of the less common but potentially serious side effects of Yervoy?

Yervoy can result in severe immune-mediated side effects (side effects that result from activation of the immune system). These side effects—which can involve any organ system—typically begin during treatment with Yervoy, but can also show up months after treatment with Yervoy ends. The most common severe immune-mediated side effects are the following:

• Enterocolitis (inflammation of the intestines; can cause tears or holes in the intestines)
• Hepatitis (inflammation of the liver; can lead to liver failure)
• Dermatitis (inflammation of the skin)
• Neuropathy (inflammation of the nerves; can lead to paralysis)
• Endocrinopathy (inflammation of the glands that produce hormones; may affect how these glands function)
• Inflammation of the eyes.

This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.
What can patients do to help alleviate or prevent discomfort and side effects?

• Pay careful attention to the physician’s instructions, and discuss side effects with your physician.

Are there any special precautions patients should be aware of before starting treatment?

• Patients should inform their physician about all medical conditions, including autoimmune diseases, organ transplantation, and liver damage.
• Patients should inform their physician of any other medication or supplement they are taking (whether prescription or over-the-counter).
• Patients should inform their physician if they are pregnant, breastfeeding or planning a family in the near future.

When should patients notify their physician?

Tell your doctor if you experience any side effects that bother you or don’t go away. Watch for signs of serious side effects and report these to your doctor immediately: symptoms of enterocolitis may include diarrhea or more bowel movements than usual, blood in your stools or dark sticky stools, or stomach pain or tenderness; symptoms of hepatitis may include jaundice (yellowing of the skin or the whites of your eyes), dark urine, nausea and vomiting, pain on right side of stomach, and easy bruising or bleeding; symptoms of dermatitis may include skin rash, sores in your mouth, or skin blistering or peeling; symptoms of neuropathy may include unusual weakness of the legs, arms or face, or numbness or tingling in the hands or feet; symptoms of endocrinopathy include persistent or unusual headaches, unusual sluggishness or weight gain, feeling cold all the time, changes in mood or behavior, or dizziness or fainting; and symptoms of eye inflammation may include changes in vision or eye pain or redness.

What is a package insert?
A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers.  A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.

Copyright © 2011 CancerConnect Last updated 04/11.

Important Limitations of Use

The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor.  We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.

As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information.  Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment in selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.

DISCLAIMER OF WARRANTIES

CANCERCONSULTANTS.COM SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN.  CANCERCONSULTANTS.COM DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.

Generic Name: Pazopanib

Trade Name: Votrient®

How is this drug used? Votrient is used for the treatment of advanced renal cell (kidney) cancer in adults.

What is the mechanism of action? Votrient may help slow or prevent the growth of new blood vessels, which deprives the cancer of the oxygen and nutrients it needs to grow.

How is Votrient given (administered)? Votrient is administered orally in the form of a tablet. It is taken on an empty stomach (at least one hour before or two hours after food).

How are patients monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Votrient. Typically, blood will be drawn to check levels of blood cells and to monitor functions of some organ systems. Patients may also undergo physical examinations, scans or other measures to assess side effects and response to therapy.

What are the most common (occur in 20% or more of patients) side effects of treatment with Votrient?

• Diarrhea
• High blood pressure
• Hair color changes
• Nausea
• Loss of appetite
• Vomiting

What are some of the less common but potentially serious side effects of Votrient?

• Liver problems
• High blood pressure
• Irregular or fast heartbeat or fainting
• Heart attack or stroke
• Bleeding problems
• Tear in stomach or intestinal wall (perforation) or bleeding
• Thyroid problems

This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.
What can patients do to help alleviate or prevent discomfort and side effects?

• Pay careful attention to the physician’s instructions, and discuss side effects with your physician.

Are there any special precautions patients should be aware of before starting treatment?

• Patients should inform their physician of any other medication they are taking (whether prescription or over-the-counter), as they may interact with treatment. Drugs that are particularly likely to interact with treatment include some antibiotics, some drugs used to treat HIV, some drugs used to treat depression, and some drugs used to treat irregular heart beats.
• Patients should inform their physician if they drink grapefruit juice.
• Patients should inform their physician if they are pregnant, breastfeeding or planning a family in the near future. Votrient can harm an unborn child.
• Patients should inform their physician about all medical conditions, including liver problems, high blood pressure, heart problems, stroke, coughing up blood, bleeding in stomach or intestines, tear (perforation) or abnormal connection (fistula) in your stomach or intestines, thyroid problems, and recent or planned surgery.

When should patients notify their physician?

Tell your doctor if you experience any side effects that bother you or don’t go away. Symptoms of liver problems (as well as symptoms of the other serious side effects listed above) should be reported immediately. Symptoms of liver problems include yellowing of the skin or whites of the eye (jaundice), dark urine, tiredness, nausea or vomiting, loss of appetite, pain on right side of stomach, or easy bruising.

What is a package insert?
A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers. A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.

Copyright © 2011 CancerConnect Last updated 04/11.

Important Limitations of Use

The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor. We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.

As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information. Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment in selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.

DISCLAIMER OF WARRANTIES

CANCERCONSULTANTS.COM SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN. CANCERCONSULTANTS.COM DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.